CNCE Average Annual Return 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into CNCE

Also see:
CNCE stock yearly return 2014
CNCE stock yearly return 2015
CNCE stock yearly return 2016
CNCE stock yearly return 2017
CNCE stock yearly return 2018
CNCE stock yearly return 2019
CNCE stock yearly return 2020
CNCE stock yearly return 2021
CNCE stock yearly return 2022
CNCE YTD return
Compare CNCE average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 02/14/2014
End date: 03/06/2023
Start price/share: $14.07
End price/share: $8.37
Dividends collected/share: $0.00
Total return: -40.51%
CNCE Average Annual Return: -5.57%
Starting investment: $10,000.00
Ending investment: $5,949.63
Years: 9.06

CNCE average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 inhibitor that Co. discovered through the application of its DCE Platform® (deuterated chemical entity platform). Co. is evaluating CTP-543 in a Phase 3 clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. In addition to its wholly-owned development programs, Co. has entered into collaborative arrangements with companies to develop deuterium-modified versions of their marketed products. The CNCE average annual return since 2014 is shown above.

The Average Annual Return on the CNCE average annual return since 2014 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether CNCE average annual return since 2014 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the CNCE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree CNCE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Concert Pharmaceuticals (CNCE) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

CNMD Average Annual Return
CNSP Average Annual Return
CNTX Average Annual Return
COCP Average Annual Return
CODX Average Annual Return
COGT Average Annual Return
COLL Average Annual Return
COM Average Annual Return
COO Average Annual Return
COOL Average Annual Return
More Healthcare companies »


CNCE Average Annual Return 10 Years | | Copyright © 2021 - 2023, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.